“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs
This article was originally published in The Tan Sheet
Executive Summary
The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
You may also be interested in...
FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
FDA says industry concerns about the implied finality of "not approvable" letters led it to change how it responds to drug applications
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
A proposed rule on consumer topical antimicrobial products is scheduled for March 2006 release, according to HHS' semi-annual "unified agenda" published in the Federal Register Oct. 31
CHPA “approvable”letter comments
FDA "should clearly define specific deficiencies" in an application in a complete response letter, the Consumer Healthcare Products Association says in Oct. 18 comments on the agency's proposed rule to discontinue use of "approvable" and "not approvable" letters. Defining deficiencies "would avoid presentation of new issues at a later date after a complete response letter has been issued, and minimize the potential for cycles of complete response letters," CHPA states. The association "supports" FDA's proposal to use complete response letters once the review cycle is complete but an application is not ready for approval. The proposed reg was published in July (1"The Tan Sheet" July 26, 2004, p. 11)...